Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4986 studies found for:    Immunodeficiency
Show Display Options
Rank Status Study
21 Not yet recruiting Neonatal Screening of Severe Combined Immunodeficiencies
Conditions: Severe Combined Immunodeficiency;   Neonatal Screening
Intervention:
22 Completed Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms
Condition: Common Variable Immunodeficiency
Intervention:
23 Withdrawn A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection
Condition: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Intervention: Drug: No intervention
24 Completed
Has Results
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
Condition: Human Immunodeficiency Virus Infections
Intervention: Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
25 Completed Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)
Condition: Severe Combined Immunodeficiency
Intervention: Drug: Gene-Transduced Autologous CD34+ Stem Cells
26 Completed
Has Results
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Intervention: Biological: GAMUNEX-C
27 Recruiting Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Biological: IGIV-C 10%;   Biological: IGSC 20%
28 Completed Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
Condition: Immunologic Deficiency Syndrome
Intervention: Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
29 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
30 Completed An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS);   Human Immunodeficiency Virus Infections
Intervention: Drug: Serostim®
31 Completed
Has Results
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
Condition: Human Immunodeficiency Virus Infections
Intervention: Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
32 Completed Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)
Condition: Primary Immune Deficiency
Intervention: Biological: Immune globulin subcutaneous (Human)
33 Completed STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
Condition: Common Variable Immunodeficiency
Intervention: Drug: STA-5326
34 Active, not recruiting Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant
Conditions: Immune System Disorder;   Severe Combined Immunodeficiency
Interventions: Drug: cyclosporine;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
35 Completed
Has Results
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Condition: Primary Immunodeficiency (PID)
Intervention: Drug: Immune Globulin Intravenous (Human), 10%
36 Completed Medication Adherence in Human Immunodeficiency Virus (HIV)
Condition: Human Immunodeficiency Virus
Interventions: Behavioral: Staff-delivered intervention sessions;   Other: Demographic Questionnaire;   Other: Questionnaires
37 Completed
Has Results
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Conditions: Primary Immunodeficiency;   Common Variable Hypogammaglobulinemia;   X-linked Hypogammaglobulinemia;   Hypogammaglobulinemia;   Immunodeficiency With Hyper-IgM;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex (Intravenous immunoglobulin)
38 Completed Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS);   Human Immunodeficiency Virus Infections
Interventions: Drug: Serostim®;   Drug: Placebo
39 Recruiting Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Biological: Ad26.Mos.HIV;   Biological: MVA-Mosaic;   Drug: Placebo
40 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.